文献速递造血干细胞移植与细胞治疗

CAR-T细胞治疗后入住重症监护患者的结局:CARTTAS国际多中心观察性队列研究

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
PubMed 文献 · Lancet Haematol · 2021-01-01

多变量分析显示衰弱、细菌感染和入住24小时内使用挽救性治疗与90天死亡率独立相关。作者认为重症监护管理是CAR-T治疗不可或缺的组成部分,应标准化。

要点

  • 入住时42%为孤立性细胞因子释放综合征,39%合并ICANS,3%为孤立性ICANS。

核心结论

  • 重症监护管理是CAR-T细胞治疗不可或缺的组成部分,应予以标准化。
  • 需开展研究以改善这些高危患者的感染预防与治疗。

研究设计与样本

  • 国际、多中心、观察性队列研究,在法国、西班牙、美国、英国、俄罗斯、加拿大、德国和奥地利的21个ICU开展。
  • 纳入年龄≥18岁、过去30天内接受CAR-T细胞治疗、因任何原因入住ICU的患者;回顾性纳入2018年2月1日至2019年2月1日入住者,前瞻性纳入2019年3月1日至2020年2月1日入住者。
  • 942例接受CAR-T治疗的患者中,258例(27%)需入住ICU,241例(26%)纳入分析。
  • 主要终点为90天死亡率,采用Cox比例风险模型识别与死亡率相关的因素。

主要发现

  • 入住ICU时初始评估:孤立性细胞因子释放综合征101例(42%),细胞因子释放综合征合并ICANS 93例(39%),孤立性ICANS 7例(3%)。
  • 入住ICU 1天内3-4级细胞因子释放综合征见于50/200例(25%),3-4级ICANS见于38/108例(35%);细菌感染发生30例(12%)。
  • 入住ICU 24小时内使用挽救性治疗75例(31%),主要为血管活性药物65例(27%)。

临床怎么用

  • CAR-T治疗后患者应密切监测,及时识别需要ICU级别的器官支持。
  • 对合并衰弱、细菌感染或需早期挽救性治疗的患者应加强风险评估与干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of this study was to describe management of critically ill CAR T-cell recipients in intensive care. METHODS: This international, multicentre, observational cohort study was done in 21 intensive care units in France, Spain, the USA, the UK, Russia, Canada, Germany, and Austria. Eligible patients were aged 18 years or older; had received CAR T-cell therapy in the past 30 days; and had been admitted to intensive care for any reason. Investigators retrospectively included patients admitted between Feb 1, 2018, and Feb 1, 2019, and prospectively included patients admitted between March 1, 2019, and Feb 1, 2020. Demographic, clinical, laboratory, treatment, and outcome data were extracted from medical records. The primary endpoint was 90-day mortality. Factors associated with mortality were identified using a Cox proportional hazard model. FINDINGS: 942 patients received CAR T-cell therapy, of whom 258 (27%) required admission to intensive care and 241 (26%) were included in the analysis. Admission to intensive care was needed within median 4·5 days (IQR 2·0-7·0) of CAR T-cell infusion. 90-day mortality was 22·4% (95% CI 17·1-27·7; 54 deaths). At initial evaluation on admission, isolated cytokine release syndrome was identified in 101 patients (42%), cytokine release syndrome and ICANS in 93 (39%), and isolated ICANS in seven (3%) patients. Grade 3-4 cytokine release syndrome within 1 day of admission to intensive care was found in 50 (25%) of 200 patients and grade 3-4 ICANS in 38 (35%) of 108 patients. Bacterial infection developed in 30 (12%) patients. Life-saving treatments were used in 75 (31%) patients within 24 h of admission to intensive care, primarily vasoactive drugs in 65 (27%) patients. Factors independently associated with 90-day mortality by multivariable analysis were frailty (hazard ratio 2·51 [95% CI 1·37-4·57]), bacterial infection (2·12 [1·11-4·08]), and lifesaving therapy within 24 h of admission (1·80 [1·05-3·10]). INTERPRETATION: Critical care management is an integral part of CAR T-cell therapy and should be standardised. Studies to improve infection prevention and treatment in these high-risk patients are warranted. FUNDING: Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Azoulay É, Castro P, Maamar A, et al. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021. PMID: 33894170. doi:10.1016/S2352-3026(21)00060-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。